First National Bank & Trust Co. of Newtown Cuts Stock Position in Bristol-Myers Squibb (NYSE:BMY)

First National Bank & Trust Co. of Newtown lowered its position in Bristol-Myers Squibb (NYSE:BMY) by 1.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 30,260 shares of the biopharmaceutical company’s stock after selling 595 shares during the period. First National Bank & Trust Co. of Newtown’s holdings in Bristol-Myers Squibb were worth $1,553,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of BMY. OFI Invest Asset Management purchased a new stake in Bristol-Myers Squibb during the 3rd quarter worth approximately $25,000. True Wealth Design LLC purchased a new stake in Bristol-Myers Squibb during the 4th quarter worth approximately $26,000. Milestone Investment Advisors LLC purchased a new stake in Bristol-Myers Squibb during the 3rd quarter worth approximately $27,000. Coppell Advisory Solutions LLC purchased a new stake in Bristol-Myers Squibb during the 2nd quarter worth approximately $28,000. Finally, Blue Bell Private Wealth Management LLC grew its position in Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.6 %

Bristol-Myers Squibb stock traded up $0.31 during trading on Friday, reaching $48.61. The stock had a trading volume of 2,803,687 shares, compared to its average volume of 15,608,562. Bristol-Myers Squibb has a 52-week low of $47.58 and a 52-week high of $70.93. The business has a 50 day moving average price of $51.25 and a 200 day moving average price of $51.57. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. The stock has a market cap of $98.52 billion, a PE ratio of 12.56, a P/E/G ratio of 1.44 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter in the previous year, the firm earned $1.82 earnings per share. The firm’s quarterly revenue was up .6% on a year-over-year basis. On average, analysts predict that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.94%. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

Analyst Upgrades and Downgrades

BMY has been the topic of several research analyst reports. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Finally, StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $61.18.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.